Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu, +22

The Lancet Oncology

Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma

Natsuko Okita, Ken Kato, Daisuke Takahari, +8

Gastric Cancer

Surgical OncologyGastrointestinal OncologyMedicineNeuroendocrine DisorderGastroenterology +5

Impact of Insulin-Like Growth Factor Type 1 Receptor, Epidermal Growth Factor Receptor, and HER2 Expressions on Outcomes of Patients with Gastric Cancer

Junichi Matsubara, Yasuhide Yamada, Yoshinori Hirashima, +7

Clinical Cancer Research

Pharmacokinetic parameters from 3‐Tesla DCE‐MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis

Yoshinori Hirashima, Yasuhide Yamada, Ukihide Tateishi, +11

International Journal of Cancer

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Masanori Terashima, Young‐Woo Kim, +21

˜The œLancet. Gastroenterology & hepatology

Chemotherapy Versus PlaceboSurgical OncologyGastrointestinal OncologyMedicineGastroenterology +6

Relationships of Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor Expression to Clinical Outcomes in Patients with Colorectal Cancer

Daisuke Takahari, Yasuhide Yamada, Natuko T. Okita, +9

Oncology

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma

Takahiro Horimatsu, Norisuke Nakayama, Toshikazu Moriwaki, +11

International Journal of Clinical Oncology

Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma

Hidetoshi Hayashi, Tokuzo Arao, Kazuko Matsumoto, +14

Oncotarget

Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer

Yoshinori Hirashima, Yasuhide Yamada, Junichi Matsubara, +9

Cancer Science

Tumor BiologyResidual TumorSurgical OncologyAngiogenesisGastrointestinal Oncology +12

A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors

Koichiro Watanabe, Satoshi Otsu, Yoshinori Hirashima, +12

Cancer Chemotherapy and Pharmacology

Tumor BiologyOncologyMedicineCancer GrowthPathology +6